[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370232-105":59,"doc-detail-370232-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preclinical-characterization-of-xb002-an-anti-tissue-factor-antibodydrug-conjugate-for-the-treatment-of-solid-tumors","Preclinical Characterization of XB002 - an Anti-Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors","","Preclinical characterization evaluates XB002, an anti–tissue factor (TF) antibody–drug conjugate intended to selectively deliver a cytotoxic payload to TF-expressing solid tumors while reducing TF-related adverse events, especially bleeding. The conjugate links a zovodotin linker-payload to a TF-binding mAb (clone 25A3). In vitro work shows no interference with clotting-factor activation and TF-driven internalization with potent cytotoxicity. In xenograft and patient-derived models, weekly dosing yields complete tumor regression in multiple cancers, with nonhuman primate data showing therapeutic-range exposure and no bleeding or neutropenia.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-characterization-of-xb002-an-anti-tissue-factor-antibodydrug-conjugate-for-the-treatment-of-solid-tumors/370232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-characterization-of-xb002-an-anti-tissue-factor-antibodydrug-conjugate-for-the-treatment-of-solid-tumors/370232.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does XB002 aim to address in solid tumors?","Question",{"text":112,"@type":113},"XB002 targets tissue factor, which is overexpressed in many cancers and is linked to poor outcomes. It is designed to deliver a cytotoxic payload to TF-expressing tumors while minimizing bleeding-related adverse events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the XB002 mechanism relate to antibody–drug conjugate processing?",{"text":117,"@type":113},"After binding TF on tumor cells, the antibody–TF complex is internalized and routed to lysosomes, where the payload is cleaved and released to disrupt essential cellular processes and kill cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What preclinical evidence supports XB002’s antitumor activity and safety signals?",{"text":121,"@type":113},"In vivo, XB002 dosing produced strong tumor inhibition and complete regression in certain xenograft models. In nonhuman primates, it showed favorable pharmacokinetics within the desired therapeutic range without detectable bleeding or neutropenia.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370232,1790304941,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors  \nSeema Kantak1, Raffaella Faggioni2,\\#, Allen G. Cai3,\\#, Maryam M. Bhatti3,\\#, Jing Li2,\\#, Inna Vainshtein2, Jackie Cheng2, Brian A. Mendelsohn1, Jacques Gaudreault3,\\#, Thi-Sau Migone3,\\#,  \nand Jan-Willem Theunissen3,\\#  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Tissue factor (TF) is overexpressed in various cancers and is typically associated with poor clinical outcomes. XB002 is an anti-TF antibody–drug conjugate designed to selectively deliver a cytotoxic payload to TF-expressing tumors while minimizing TFrelated adverse events, particularly bleeding. The conjugate consists of a zovodotin linker–payload attached to a mAb (clone 25A3) that binds TF with high affinity (KD ¼ 0.86 nmol/L) . In vitro coagulation assays confirmed that 25A3 does not interfere with the clotting cascade; even at a concentration of 100 nmol/L, it did not affect the activation of coagulation factor X orthrombin generation. XB002 demonstrated efficient internalization in TF-expressing cancer cell lines, exhibiting potent cytotoxicity at subnanomolar concentrations. In the HPAF-II xenograft model, a regimen of XB002 (1.5 mg/kg, i.v.)\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | administered once weekly for two weeks achieved complete tumor regression, with no detectable tumor growth up to five weeks after the second dose. In murine patient-derived xenograft models, a single dose of XB002 (10 mg/kg, i.v.) inhibited tumor growth across multiple cancer models, including bladder, cervical, gastric, head and neck squamous cell carcinoma, and non– small cell lung cancers. Remarkably, complete tumor regression was observed in the cervical cancer and head and neck squamous cell carcinoma models within 30 days of treatment. In nonhuman primate studies, XB002 demonstrated favorable pharmacokinetics with exposure in the desired therapeutic range and no signs of bleeding or neutropenia. Collectively, these data highlight XB002’s broad-spectrum antitumor activity and strongly support its further clinical development. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTissue factor (TF, also known as thromboplastin, coagulation factor III, or CD142) is a 47-kDa transmembrane glycoprotein that plays an important role in coagulation (1–3). Abnormal expression of TF outside subendothelial tissues is reported to be associated with cancer. TFis overexpressed in cervical, ovarian, head and neck, bladder, lung, urogenital, gastrointestinal, breast, and other solid tumors (2, 4–6), and its expression is associated with poor outcomes, including shorter overall survival and a higher incidence of metastasis (2, 4, 7–14). This association of TF expression and cancer development and poor prognosis is believed to be related to the oncogenic activity of TF, includingthe promotion of an","cbCaieVfYKrgW55c","https://ap.wps.com/l/cbCaieVfYKrgW55c","pdf",3398293,"English","# Introduction\n## Tissue factor as a cancer-associated target\n## Rationale for anti-TF antibody–drug conjugates\n## Key considerations in anti-TF ADC development","[{\"question\":\"What problem does XB002 aim to address in solid tumors?\",\"answer\":\"XB002 targets tissue factor, which is overexpressed in many cancers and is linked to poor outcomes. It is designed to deliver a cytotoxic payload to TF-expressing tumors while minimizing bleeding-related adverse events.\"},{\"question\":\"How does the XB002 mechanism relate to antibody–drug conjugate processing?\",\"answer\":\"After binding TF on tumor cells, the antibody–TF complex is internalized and routed to lysosomes, where the payload is cleaved and released to disrupt essential cellular processes and kill cancer cells.\"},{\"question\":\"What preclinical evidence supports XB002’s antitumor activity and safety signals?\",\"answer\":\"In vivo, XB002 dosing produced strong tumor inhibition and complete regression in certain xenograft models. In nonhuman primates, it showed favorable pharmacokinetics within the desired therapeutic range without detectable bleeding or neutropenia.\"}]","Preclinical Characterization of XB002 - an Anti-Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors | PDF",1790187507,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae8aca687e0c2c7b09a1afdb25f4f734.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5016eda47a1bc64970c5174acdff0f8.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d0ebd3253641f67eec15403ea405b2e.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1309f4a459edb54a8d63a92ac5494ed1.webp",980,1311]